An indirect comparison of the efficacy of bevacizumab plus carboplatin and paclitaxel versus pemetrexed with cisplatin in patients with advanced or recurrent non-squamous adenocarcinoma non-small cell lung cancer.

Abstract

OBJECTIVE There are two new treatment options available for the treatment of adenocarcinoma histology non-small cell lung cancer (NSCLC) which offer improved benefit in terms of progression-free (PFS) and overall survival (OS) over chemotherapy. Both bevacizumab and pemetrexed when combined with chemotherapy significantly increase PFS and OS in patients… (More)
DOI: 10.1185/03007995.2011.626019

Topics

Cite this paper

@article{Nuijten2011AnIC, title={An indirect comparison of the efficacy of bevacizumab plus carboplatin and paclitaxel versus pemetrexed with cisplatin in patients with advanced or recurrent non-squamous adenocarcinoma non-small cell lung cancer.}, author={Mark J. C. Nuijten and Rick Aultman and Javier de Castro Carpe{\~n}o and Alain Vergnen{\'e}gre and Christos Chouaid and Stefan Walzer and Uwe Siebert}, journal={Current medical research and opinion}, year={2011}, volume={27 11}, pages={2193-201} }